Predictors of baseline and prospective change in standardized height in total cohort; results of stepwise multiple linear regression analyses.

<p>The prospective change in height SDS during one year of observation was positively associated with higher BAP and TRAP5b SDS, lower baseline height SDS and rhGH therapy.</p><p>Interestingly, physical activity showed a positive association to prospective growth.</p><p>A case-control study was performed to obtain an unbiased analysis of the impact of rhGH on the bone marker pattern. For 41 rhGH treated patients an equal number of untreated control subjects matched by age, sex, country of residence, CKD duration, eGFR and serum phosphorus, iPTH and CRP was identified (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113482#pone.0113482.t005" target="_blank">Table 5</a>).</p><p>Predictors of baseline and prospective change in standardized height in total cohort; results of stepwise multiple linear regression analyses.</p

Bone markers in groups matched for GH treatment.

<p>Bone markers in groups matched for GH treatment.</p

Distribution of serum bone markers by CKD stage.

<p>Data are given as mean ± SD or median (interquartile range) P values indicate difference of age- and sex-adjusted SDS from reference population. Different superscript letters indicate significant differences (p<0.05) between CKD stages (according to ANOVA using Student-Newman-Keuls grouping).</p><p>A, B & C: Student-Newman-Keuls Grouping—Means with the same letter are not significantly different.</p><p>Distribution of serum bone markers by CKD stage.</p

Subject characteristics.

<p>Data are given as mean ± SD, median (interquartile range) or n (%) as appropriate.</p><p>At the time of bone marker assessment, 42 children (7.4%) were receiving rhGH treatment, excluding 4 patients who either started or stopped rhGH therapy within 3 months prior to analysis. 38 patients were consistently treated with rhGH during the follow-up period of 6–12 months. rhGH treated patients originated from 7 of the 12 participating countries, had a longer preceding duration of CKD (8.1±4.3 vs 5.9±4.5 years, p<0.003), were taller (-0.89±0.87 vs. -1.4±1.4 SDS, p<0.0002) and showed marginally better current growth rates (0.07±0.38 vs. -0.04±0.38, p = 0.08) compared to all non-rhGH treated patients.</p><p>Subject characteristics.</p

Predictors of standardized bone marker concentrations; results of stepwise multiple linear regression analyses.

<p>Predictors of standardized bone marker concentrations; results of stepwise multiple linear regression analyses.</p

Patient inclusion criteria and subgroups for cross-sectional analysis of bone markers, influence of rhGH treatment and predictors of height and growth.

<p>Patient inclusion criteria and subgroups for cross-sectional analysis of bone markers, influence of rhGH treatment and predictors of height and growth.</p